From Inquiry to Investigation to Insight (I3): Clinical Clarity in Non-small Cell Lung Cancer
credits/contact hours
Register Now |  Learning Objectives |  Registration Fee |  Agenda |  Accreditation

Learn From the Experts About Clinical Clarity in NSCLC

Learn strategies to improve outcomes for your patients with non-small cell lung cancer.

Atlanta, GA • October 5, 2019

Register Now


Upon completion of this activity, participants should be better able to:

  • Evaluate recent updates regarding biomarker testing and molecular profiling used to guide management decisions for metastatic NSCLC
  • Devise treatment plans for patients with locally advanced NSCLC
  • Evaluate efficacy and safety data supporting the use of targeted and immune checkpoint inhibitor therapy used to treat NSCLC
  • Select therapy in accordance with evidence-based best practices
  • Apply clinical approaches to mitigate adverse events associated with targeted and ICI therapy
  • Manage drug–drug and drug–disease interactions in NSCLC 


  Member Non-Member
Registration $50.00 $75.00



7:00–7:30 am Registration    
7:30–8:30 am Noncertified Breakfast Symposium    
8:30–8:45 am Welcome and Disease Overview
8:45–9:20 am Selecting Treatments Using Biomarker Testing and Molecular Profiling (0.50 contact hour)
Review of strategies for planning therapy based on results of biomarker tests, liquid biopsies, as well as next-generation sequencing and tumor mutational burden profiles.
9:20–10:05 am Managing Early Stage and Locally Advanced NSCLC (0.75 contact hour)
Discussion of evidence-based management of stage III disease using a multimodal approach that includes surgery, adjuvant chemotherapy, chemoradiation, and immunotherapy.
10:05–10:20 am Break    
10:20–11:10 am The Role of Immune Checkpoint Inhibitors With and Without Combination Therapy for Nonmutated Metastatic NSCLC (0.75 contact hour)
Analysis of therapeutic approaches using immune checkpoint inhibitors alone or with other agents in first-line setting and beyond.
11:10–11:45 am Managing Immune-Related Adverse Events (0.50 contact hour)
Review of clinical and patient education strategies for identifying, mitigating, and addressing adverse events associated with immune checkpoint inhibitors.
11:45 am–1:15 pm Noncertified Lunch Symposium    
1:15–1:45 pm Managing EGFR+ Metastatic NSCLC (0.50 contact hour)
Overview of the rationale for targeting EGFR-mutated NSCLC, followed by an evaluation of clinical data and best practices supporting the safe and effective use of EGFR inhibitors in the first-line setting and beyond.
1:45–2:15 pm Managing ALK+ and ROS1+ Metastatic NSCLC (0.50 contact hour)
Overview of the rationale for targeting ALK- and ROS1-mutated NSCLC, followed by an evaluation of clinical data and best practices supporting the safe and effective use of ALK inhibitors in the first-line setting and beyond.
2:15–2:35 pm Managing Patients With Other Mutations in Metastatic NSCLC (0.25 contact hour)
Evaluation of the rationale for and clinical data supporting targeting driver mutations in NSCLC, such as BRAF, HER2, KRAS, MEK1, MET, NRAS, PIK3CA, and RET.
2:35–2:45 pm Break and iPad Raffle Drawing
2:45–3:15 pm Identifying and Avoiding Drug Interactions (0.50 contact hour)
Discussion of best practices for mitigating drug-drug interactions and drug-disease interactions.
3:15–3:30 pm The Horizon: Upcoming Practice-Changing Trials (0.25 contact hour)
Appraisal of clinical trials planned or in progress in lung cancer for which preliminary or updated data release has occurred in the past 12 months or is expected in the next 6 months.
3:30–4:00 pm Consult the Experts: Case Challenges From Conference Participants (0.50 contact hour)
Discussion of clinical decision points involved in challenging patient cases, with a focus on how patient disease characteristics and personal preferences can be used to guide clinical decision-making.
4:00 pm Program Adjourns

*Program times are subject to change.

Atlanta, GA • October 5, 2019

Register Now

Physicians: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Annenberg Center for Health Sciences at Eisenhower, and Harborside Medical Education. The Annenberg Center is accredited by the ACCME to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this live activity for a maximum of 5.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: The Annenberg Center for Health Sciences at Eisenhower is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Credit for completing the conference will include pharmacology hours (number of hours TBD).  

A maximum of 5.0 contact hours may be earned for successful completion of this activity.

Pharmacists: The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program has been assigned ACPE Universal Program TBD.

This program is designated for up to 5.0 contact hours (0.500 CEUs) of continuing pharmacy education credit.

PAs: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society.

PAs may receive a maximum of 5.0 Category 1 credits for completing this activity.


This conference, certified for
CME/CE/CPE credit, is jointly provided by:

in collaboration with:

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.